Half-year report · Q2
3353.TEDINET S100WUVY
Period2025-03-01 → 2025-08-31
Filed2025-10-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥26.9bn | 2025-03-01 → 2025-08-31 | Cons. | Net sales |
| Revenue | ¥48.4bn | 2024-03-01 → 2025-02-28 | Cons. | Net sales (5-year summary) |
| Revenue | ¥22.7bn | 2024-03-01 → 2024-08-31 | Cons. | Net sales |
| Operating income | ¥744m | 2025-03-01 → 2025-08-31 | Cons. | Operating income |
| Operating income | ¥828m | 2024-03-01 → 2024-08-31 | Cons. | Operating income |
| Ordinary income | ¥880m | 2025-03-01 → 2025-08-31 | Cons. | Ordinary income |
| Ordinary income | ¥1.8bn | 2024-03-01 → 2025-02-28 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥853m | 2024-03-01 → 2024-08-31 | Cons. | Ordinary income |
| Profit before tax | ¥1.0bn | 2025-03-01 → 2025-08-31 | Cons. | Income before income taxes |
| Profit before tax | ¥1.1bn | 2024-03-01 → 2024-08-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥667m | 2025-03-01 → 2025-08-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.1bn | 2024-03-01 → 2025-02-28 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥710m | 2024-03-01 → 2024-08-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥691m | 2025-03-01 → 2025-08-31 | Cons. | Profit loss |
| Net income | ¥728m | 2024-03-01 → 2024-08-31 | Cons. | Profit loss |
| Total assets | ¥37.9bn | at 2025-08-31 | Cons. | Assets |
| Total assets | ¥34.2bn | at 2025-02-28 | Cons. | Assets |
| Total assets | ¥33.1bn | at 2024-08-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥22.6bn | at 2025-08-31 | Cons. | Liabilities |
| Total liabilities | ¥19.5bn | at 2025-02-28 | Cons. | Liabilities |
| Net assets / equity | ¥15.3bn | at 2025-08-31 | Cons. | Net assets |
| Net assets / equity | ¥14.7bn | at 2025-02-28 | Cons. | Net assets |
| Net assets / equity | ¥14.4bn | at 2024-08-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥8.6bn | at 2025-08-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥6.8bn | at 2025-02-28 | Cons. | Cash and deposits |
| Cash & equivalents | ¥8.1bn | at 2025-08-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥6.6bn | at 2025-02-28 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥8.1bn | at 2024-08-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥7.6bn | at 2024-02-29v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥1.5bn | 2025-03-01 → 2025-08-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.2bn | 2024-03-01 → 2025-02-28 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.5bn | 2024-03-01 → 2024-08-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥987m | 2025-03-01 → 2025-08-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.1bn | 2024-03-01 → 2025-02-28 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥675m | 2024-03-01 → 2024-08-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥1.0bn | 2025-03-01 → 2025-08-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥1.0bn | 2024-03-01 → 2025-02-28 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥354m | 2024-03-01 → 2024-08-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥177.23 | 2025-03-01 → 2025-08-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥301.35 | 2024-03-01 → 2025-02-28 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥188.75 | 2024-03-01 → 2024-08-31 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 38.6% | at 2025-08-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 41.2% | at 2025-02-28 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 41.6% | at 2024-08-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 44
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2025-03-01 → 2025-08-31 | −¥561m |
| Reconciling Itemsreconciling | revenue intersegment | 2025-03-01 → 2025-08-31 | −¥561m |
| Reconciling Itemsreconciling | segment profit | 2025-03-01 → 2025-08-31 | −¥94m |
| jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segment | revenue | 2025-03-01 → 2025-08-31 | ¥13.1bn |
| jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segment | revenue external | 2025-03-01 → 2025-08-31 | ¥13.1bn |
| jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segment | segment profit | 2025-03-01 → 2025-08-31 | ¥658m |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | revenue | 2025-03-01 → 2025-08-31 | ¥4.4bn |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | revenue external | 2025-03-01 → 2025-08-31 | ¥4.4bn |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | revenue intersegment | 2025-03-01 → 2025-08-31 | ¥300,000 |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | segment profit | 2025-03-01 → 2025-08-31 | ¥14m |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | revenue | 2025-03-01 → 2025-08-31 | ¥9.9bn |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | revenue external | 2025-03-01 → 2025-08-31 | ¥9.4bn |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | revenue intersegment | 2025-03-01 → 2025-08-31 | ¥555m |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | segment profit | 2025-03-01 → 2025-08-31 | ¥90m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | revenue | 2025-03-01 → 2025-08-31 | ¥126m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | revenue external | 2025-03-01 → 2025-08-31 | ¥120m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | revenue intersegment | 2025-03-01 → 2025-08-31 | ¥5m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | segment profit | 2025-03-01 → 2025-08-31 | ¥75m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-03-01 → 2025-08-31 | ¥27.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-03-01 → 2025-08-31 | ¥26.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2025-03-01 → 2025-08-31 | ¥561m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-03-01 → 2025-08-31 | ¥837m |
| Reconciling Itemsreconciling | revenue | 2024-03-01 → 2024-08-31 | −¥401m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-03-01 → 2024-08-31 | −¥401m |
| Reconciling Itemsreconciling | segment profit | 2024-03-01 → 2024-08-31 | −¥110m |
| jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segment | revenue | 2024-03-01 → 2024-08-31 | ¥11.9bn |
| jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segment | revenue external | 2024-03-01 → 2024-08-31 | ¥11.9bn |
| jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segment | segment profit | 2024-03-01 → 2024-08-31 | ¥551m |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | revenue | 2024-03-01 → 2024-08-31 | ¥4.0bn |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | revenue external | 2024-03-01 → 2024-08-31 | ¥4.0bn |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | revenue intersegment | 2024-03-01 → 2024-08-31 | ¥300,000 |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | segment profit | 2024-03-01 → 2024-08-31 | ¥128m |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | revenue | 2024-03-01 → 2024-08-31 | ¥7.1bn |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | revenue external | 2024-03-01 → 2024-08-31 | ¥6.7bn |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | revenue intersegment | 2024-03-01 → 2024-08-31 | ¥399m |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | segment profit | 2024-03-01 → 2024-08-31 | ¥194m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | revenue | 2024-03-01 → 2024-08-31 | ¥93m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | revenue external | 2024-03-01 → 2024-08-31 | ¥91m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | revenue intersegment | 2024-03-01 → 2024-08-31 | ¥2m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | segment profit | 2024-03-01 → 2024-08-31 | ¥65m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-03-01 → 2024-08-31 | ¥23.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-03-01 → 2024-08-31 | ¥22.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-03-01 → 2024-08-31 | ¥401m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-03-01 → 2024-08-31 | ¥938m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 529
| Item | Context | Value | Unit |
|---|---|---|---|
| Subtotal ope cf | CurrentYTDDuration | 1938435000 | JPY |
| Interest and dividends income received ope cf inv cf | Prior1YTDDuration | 35523000 | JPY |
| Interest and dividends income received ope cf inv cf | CurrentYTDDuration | 53152000 | JPY |
| Interest expenses paid ope cf fin cf | Prior1YTDDuration | -27011000 | JPY |
| Interest expenses paid ope cf fin cf | CurrentYTDDuration | -48413000 | JPY |
| Income taxes paid refund ope cf | Prior1YTDDuration | -343988000 | JPY |
| Income taxes paid refund ope cf | CurrentYTDDuration | -482946000 | JPY |
| Net cash provided by used in operating activities | Prior1YTDDuration | 1501567000 | JPY |
| Net cash provided by used in operating activities | CurrentYTDDuration | 1460227000 | JPY |
| Purchase of property plant and equipment inv cf | Prior1YTDDuration | -465027000 | JPY |
| Purchase of property plant and equipment inv cf | CurrentYTDDuration | -271992000 | JPY |
| Proceeds from sales of property plant and equipment inv cf | Prior1YTDDuration | 2255000 | JPY |
| Proceeds from sales of property plant and equipment inv cf | CurrentYTDDuration | 6162000 | JPY |
| Purchase of intangible assets inv cf | Prior1YTDDuration | -22651000 | JPY |
| Purchase of intangible assets inv cf | CurrentYTDDuration | -16253000 | JPY |
| Purchase of investment securities inv cf | Prior1YTDDuration | -455290000 | JPY |
| Purchase of investment securities inv cf | CurrentYTDDuration | -132694000 | JPY |
| Proceeds from sales of investment securities inv cf | Prior1YTDDuration | 470380000 | JPY |
| Proceeds from sales of investment securities inv cf | CurrentYTDDuration | 446355000 | JPY |
| Purchase of investments in subsidiaries resulting in change in scope of consolidation inv cf | Prior1YTDDuration | － | JPY |
| Purchase of investments in subsidiaries resulting in change in scope of consolidation inv cf | CurrentYTDDuration | -1029021000 | JPY |
| Proceeds from purchase of investments in subsidiaries resulting in change in scope of consolidation inv cf | Prior1YTDDuration | 153474000 | JPY |
| Proceeds from purchase of investments in subsidiaries resulting in change in scope of consolidation inv cf | CurrentYTDDuration | － | JPY |
| Payments of loans receivable inv cf | Prior1YTDDuration | -500000000 | JPY |
| Payments of loans receivable inv cf | CurrentYTDDuration | － | JPY |
| Payments for lease and guarantee deposits inv cf | Prior1YTDDuration | -16951000 | JPY |
| Payments for lease and guarantee deposits inv cf | CurrentYTDDuration | -5515000 | JPY |
| Proceeds from collection of lease and guarantee deposits inv cf | Prior1YTDDuration | 34399000 | JPY |
| Proceeds from collection of lease and guarantee deposits inv cf | CurrentYTDDuration | 60787000 | JPY |
| Other net inv cf | Prior1YTDDuration | 124007000 | JPY |
| Other net inv cf | CurrentYTDDuration | -45172000 | JPY |
| Net cash provided by used in investment activities | Prior1YTDDuration | -675404000 | JPY |
| Net cash provided by used in investment activities | CurrentYTDDuration | -987345000 | JPY |
| Net increase decrease in short term loans payable fin cf | Prior1YTDDuration | -215000000 | JPY |
| Net increase decrease in short term loans payable fin cf | CurrentYTDDuration | -50000000 | JPY |
| Proceeds from long term loans payable fin cf | Prior1YTDDuration | 1200000000 | JPY |
| Proceeds from long term loans payable fin cf | CurrentYTDDuration | 2560000000 | JPY |
| Repayment of long term loans payable fin cf | Prior1YTDDuration | -1231970000 | JPY |
| Repayment of long term loans payable fin cf | CurrentYTDDuration | -1333769000 | JPY |
| Repayments of lease obligations fin cf | Prior1YTDDuration | -13561000 | JPY |
| Repayments of lease obligations fin cf | CurrentYTDDuration | -14074000 | JPY |
| Purchase of treasury stock fin cf | Prior1YTDDuration | － | JPY |
| Purchase of treasury stock fin cf | CurrentYTDDuration | -125000 | JPY |
| Cash dividends paid fin cf | Prior1YTDDuration | -93953000 | JPY |
| Cash dividends paid fin cf | CurrentYTDDuration | -150469000 | JPY |
| Net cash provided by used in financing activities | Prior1YTDDuration | -354484000 | JPY |
| Net cash provided by used in financing activities | CurrentYTDDuration | 1011562000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YTDDuration | 471677000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration | 1484444000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 7589368000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |